Apotex Pty Ltd v Les Laboratoires Servier (No 6)

Link copied
Case Copied 20 min read

FEDERAL COURT OF AUSTRALIA

Apotex Pty Ltd v Les Laboratoires Servier (No 6) [2012] FCA 745

Citation: Apotex Pty Ltd v Les Laboratoires Servier (No 6)
[2012] FCA 745
Parties: APOTEX PTY LTD ACN 096 916 148 v LES LABORATOIRES SERVIER and SERVIER LABORATORIES (AUST) PTY LTD ACN 004 838 500; LES LABORATOIRES SERVIER and SERVIER LABORATORIES (AUST) PTY LTD ACN 004 838 500 v APOTEX PTY LTD ACN 096 916 148, SYMBION PHARMACY SERVICES PTY LTD ACN 000 875 034, CHEM MART PTY LTD ACN 001 235 374, ASCENT PHARMACEUTICALS LTD ACN 003 854 626, ASPEN PHARMA PTY LTD, APOTEX INC and APOTEX PHARMACHEM INC
File number: NSD 657 of 2008
Judge: BENNETT J
Date of judgment: 12 July 2012
Catchwords: PRACTICE & PROCEDURE – application for a stay of proceeding pending the outcome of a divisional application in the Patent Office – discretion – s 37M of the Federal Court of Australia Act 1976 (Cth) - whether stay is in the interests of justice – where current proceeding ready for trial– allegations of delay in applying for the stay – whether there would be an overlap of issues and a duplication of evidence
Legislation:

Federal Court of Australia Act 1976 (Cth) s 37M

Patents Act1990 (Cth) ss 104, 105 and 158(2)

Cases cited:

Clorox Australia Pty Ltd v International Consolidated Business Pty Ltd (2005) 66 IPR 506 cited
Commonwealth Bank of Australia v Finance Sector Union of Australia (2003) 124 IR 453 cited
F Hoffman-La Roche AG v New England Biolabs Inc (2000) 99 FCR 56 cited
FA Faulding & Co Ltd v Bristol-Myers Squibb Co (1997) 40 IPR 511 considered
Genetics Institute Inc v Kirin-Amgen Inc (1999) 92 FCR 106 cited
Hughes Motor Services Pty Ltd v Wang Computer Pty Ltd (1978) 35 FLR 346 applied
Jefferson Ltd v Bhetcha [1979] 2 All ER 1108 cited
Les Laboratoires Servier v Apotex Pty Ltd (2010) 273 ALR 630 cited
McMahon v Gould (1982) 7 ACLR 202 cited
Rochfort v John Fairfax & Sons Limited [1972] 1 NSWLR 16 cited

Websyte Corporation Pty Limited v Alexander (No 2) [2012] FCA 562 cited

Date of hearing: 3 July 2012
Place: Sydney
Division: GENERAL DIVISION
Category: Catchwords
Number of paragraphs: 34
Counsel for the Applicant: Ms S. Goddard SC with Mr N. Murray
Solicitor for the Applicant: Freehills
Counsel for the Respondent: Mr B. Caine SC with Ms C.L. Cochrane
Solicitor for the Respondent: Allens

IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 657 of 2008

BETWEEN:

APOTEX PTY LTD ACN 096 916 148
Applicant

LES LABORATOIRES SERVIER
First Cross-Claimant

SERVIER LABORATORIES (AUST) PTY LTD
ACN 004 838 500
Second Cross-Claimant

AND:

LES LABORATOIRES SERVIER
Respondent

SERVIER LABORATORIES (AUST) PTY LTD
ACN 004 838 500
Second Respondent

APOTEX PTY LTD ACN 096 916 148
First Cross-Respondent

SYMBION PHARMACY SERVICES PTY LTD
ACN 000 875 034
Second Cross-Respondent

CHEM MART PTY LTD ACN 001 235 374
Third Cross-Respondent

ASCENT PHARMACEUTICALS LTD ACN 003 854 626

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Apotex Pty Ltd v Les Laboratoires Servier (No 6) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2012] FCA 745
Decision Date

CaseChat Overview and Summary

In the case of Apotex Pty Ltd v Les Laboratoires Servier (No 6), the central issue before the court was the application for a stay of proceeding pending the outcome of a divisional application in the Patent Office. The parties involved were Apotex Pty Ltd, the applicant, and Les Laboratoires Servier, the respondent. The matter was heard in the Federal Court of Australia, where Apotex sought a stay of proceedings against Servier pending the outcome of a divisional application in the Patent Office. This application for a stay was contested by Servier, who argued that the stay was not in the interests of justice.

The legal issues that the court had to decide included whether the stay was in the interests of justice and whether there would be an overlap of issues and duplication of evidence if the proceedings were not stayed. The court had to consider the discretion given under section 37M of the Federal Court of Australia Act 1976 (Cth). Furthermore, the court needed to weigh the practicalities and implications of the stay, such as the readiness of the current proceeding for trial and any allegations of delay in applying for the stay.

The court, after considering the arguments of both parties, concluded that the stay was not in the interests of justice. The court reasoned that the current proceeding was ready for trial, and there was a significant delay in applying for the stay. The court also highlighted that the current proceeding was likely to be more efficient as it would narrow down the issues necessary for determination in the hearings on the Divisional. The court dismissed the interlocutory application, finding that the stay would result in a substantial period of delay and potential duplication of evidence. Consequently, the court ordered that the interlocutory application be dismissed with costs.

Orders

Orders of the court

1. The interlocutory application dated 4 May 2012 be dismissed with costs.

Note:

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

As to the practicalities, Apotex points out that there are four possible outcomes of the AC Patent hearing:1.If the AC Patent is valid and infringed, Servier would not proceed on the Divisional because the latter claims are narrower and, accordingly, would be infringed as well. There would be no need for a second hearing.2.If the AC Patent is valid and not infringed, Apotex would not infringe the narrower Divisional claims and there would be no need for a second hearing.3.If the AC Patent were invalid and not infringed, Apotex would not infringe the narrower Divisional claims and there would be no need for a second hearing.4.If the AC Patent were invalid but infringed, Servier would need to proceed to determine the validity of the Divisional in order to prevent Apotex from selling its product.That is, if the AC Patent is valid, as Servier asserts, the Divisional is not relevant. If that were the case, there would be no duplication of proceedings. The only outcome on which a hearing on the Divisional Patent might arise would be the fourth outcome above. Indeed, Apotex submits there is a greater efficiency in disposing of the validity and infringement of the AC Patent, as on three of the four outcomes described above, a Divisional hearing may then be unnecessary. Apotex says that its evidence in relation to the AC Patent has already been prepared, without reference to the additional integer of the claims of the Divisional. Apotex points out that its costs, which Servier accepts would be approximately of the same order as those estimated for Servier, have already been expended and committed. Even upon the undertaking proposed by Servier, Apotex would not be in a position to recover costs for an extended period of time.Consideration I accept that Apotex has a right to have this proceeding determined. This proceeding, seeking revocation of the AC Patent, was commenced by Apotex on 9 May 2008. It has now been set down for hearing and time for that hearing has been allocated by the Court. The period of the stay if Servier’s application were successful is uncertain, but it is substantial. It is unlikely that a later hearing on either the AC Patent, the opposition to the grant of the Divisional, the Divisional Patent or the two together, would be less than 18 months and it would likely be longer. I am not certain that there are efficiencies in the two hearings taking place together. At the least, there is a different onus of proof, different claims and additional questions would arise, at least as to the novelty of claims with the additional “needles” integer and, most likely, as to questions of utility and infringements. While there may be some efficiencies in having any cases heard together, there is equally likely to be more complication. I accept if that the Divisional proceeds to grant and successfully withstands an appeal from the decision of the Commissioner, Servier would surrender the AC Patent so that there would not be a need to hear those two proceedings concurrently. However, Apotex is entitled to have the issues on the AC Patent determined. It is likely that the resolution of those issues will, in turn, narrow the issues necessary for determination in the hearings on the Divisional.